Core Viewpoint - FIL Limited has increased its stake in the company 医脉通 (02192) by acquiring 2.7155 million shares at a price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million, resulting in a new holding of about 37.1726 million shares, representing 5.04% ownership [1] Group 1 - FIL Limited's acquisition of shares indicates a strategic investment in 医脉通, reflecting confidence in the company's future prospects [1] - The transaction involved related parties, specifically Pandanus Associates Inc. and Pandanus Partners L.P., suggesting potential collaborative interests or shared investment strategies [1] - The increase in shareholding percentage to 5.04% may influence market perception and investor sentiment towards 医脉通 [1]

Group 1 - FIL Limited increased its stake in Medical Information Technology (医脉通, 02192) by acquiring 2.7155 million shares at a price of HKD 9.6301 per share, totaling approximately HKD 26.1505 million [1] - After the acquisition, FIL Limited's total shareholding in Medical Information Technology reached approximately 37.1726 million shares, representing a stake of 5.04% [1] - The transaction involves related parties: Pandanus Associates Inc. and Pandanus Partners L.P. [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 第 1 頁 共 10 ...

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of 200,000 ordinary shares to a director exercising stock options under the pre-IPO share option plan adopted on March 29, 2021, with the issuance date set for February 27, 2026 [1] Group 1 - The company will issue 200,000 ordinary shares [1] - The issuance is part of the pre-IPO share option plan adopted on March 29, 2021 [1] - The shares will be issued to a director exercising stock options [1]

Core Viewpoint - The company, 医脉通 (02192), announced the issuance of 200,000 ordinary shares to a director exercising stock options under the pre-IPO stock option plan adopted on March 29, 2021 [1] Group 1 - The issuance date for the shares is set for February 27, 2026 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 醫脈通科技有限公司 呈交日期： 2026年2月27日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 02192 | 說明 | 普通股 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | | ...

Core Viewpoint - Dahua Jixian has initiated coverage on Yimaitong (02192) with a "Buy" rating and a target price of HKD 13.5, corresponding to a projected P/E ratio of approximately 24.1 times for 2026 [1] Company Overview - Yimaitong is recognized as a leading physician platform in China, covering 88% of practicing physicians nationwide [1] - The company operates in a B2B niche market centered around physicians, which complements consumer-focused peers in the industry [1] Financial Projections - The company is expected to maintain a light asset and high-profit margin model, supporting an average annual compound growth rate of 17% in revenue and 15% in adjusted net profit from 2025 to 2027 [1] - Yimaitong's net cash position and high-profit margin outlook are viewed positively, with a potential dividend payout ratio estimated between 50% to 60% [1]

Core Viewpoint - Dahua Jixian has initiated coverage on Yimaitong (02192) with a "Buy" rating and a target price of HKD 13.5, corresponding to a projected P/E ratio of approximately 24.1 times for 2026 [1] Group 1: Company Overview - Yimaitong is recognized as a leading physician platform in China, covering 88% of practicing physicians nationwide [1] - The company operates in a B2B niche market centered around physicians, which complements consumer-focused peers in the industry [1] Group 2: Financial Projections - The company is expected to achieve a compound annual growth rate (CAGR) of 17% in revenue and 15% in adjusted net profit from 2025 to 2027 [1] - Yimaitong's business model is characterized by light asset utilization and high profit margins, supporting its financial growth outlook [1] Group 3: Cash and Dividend Outlook - The company is anticipated to maintain a strong net cash position and high profit margin prospects [1] - Potential dividend payout ratio is estimated to be between 50% and 60% [1]

Group 1 - On Lunar New Year's Eve, five listed companies announced significant mergers, acquisitions, and strategic investments, igniting market expectations for the upcoming year [1][7] - Pacific Shipping announced a strategic investment agreement with Tuo Wei Group, aiming to enhance its financial strength and expand its business in the recovering global shipping market [3] - Daren International sold 40% of its stake in Lordan Group Ltd for HKD 31.41 million, optimizing its asset structure and focusing on core business development [4] Group 2 - Li Hua Holdings Group provided a supplementary announcement regarding its asset acquisition, detailing pricing and transaction terms, which signifies a substantial step in its restructuring efforts [5] - Northern Long Dragon disclosed an acquisition aimed at enhancing its business ecosystem in both civilian and military sectors, indicating a focus on high-quality development through industry consolidation [6] - Baodi Mining's restructuring registration became effective, indicating a comprehensive integration of its gold industry chain, reflecting the ongoing trend of mergers and acquisitions in the capital market [7][8]

Investment Rating - The report provides an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, indicating a positive outlook for these stocks [1]. Core Insights - The macro and industry environment is improving due to the resolution of policy uncertainties, the release of significant clinical data, and a resurgence in global M&A activity, leading to a notable increase in investor sentiment towards innovative drugs for 2026 [4][11]. - In oncology, the PD-1/VEGF dual antibody approach is transitioning from "mechanism validation" to "clinical and industrial resonance," with multiple global Phase III trials underway, expected to catalyze approvals and data releases within the year [5][17]. - The metabolic sector is seeing growth in the cash-pay market for GLP-1 drugs, driven by limited insurance coverage and high out-of-pocket costs, prompting companies to enhance accessibility through direct sales and pricing adjustments [6][25]. - In the autoimmune space, there is a growing concentration risk among major products from multinational corporations (MNCs), with new antibody platforms expected to yield significant data in 2026, potentially leading to new business development opportunities [7]. - The central nervous system (CNS) investment focus remains on advancing Aβ monoclonal antibody treatments, with key data expected to open up early intervention market opportunities [9]. Summary by Sections Oncology - The PD-1/VEGF dual antibody's clinical and industrial certainty is strengthening, with major companies conducting multiple global Phase III trials across high-value indications [17]. - The Pan-RAS precision therapy is entering a realization phase, with key Phase III data expected in 2026 for pancreatic cancer and NSCLC [22]. Metabolic - The cash-pay market for GLP-1 drugs is expanding due to limited insurance coverage, with companies like Eli Lilly and Novo Nordisk adopting different direct-to-consumer strategies to enhance accessibility [25][26]. - Small nucleic acid therapies are expected to upgrade treatment paradigms, showing competitive data in weight loss and safety profiles when combined with GLP-1 [30]. Autoimmune - MNCs are increasingly reliant on a few blockbuster products, with structural opportunities arising from new antibody platforms expected to report data in 2026 [7]. - The trend towards oral formulations in autoimmune diseases is gaining traction, offering advantages in adherence and competitive differentiation [7]. CNS - The focus in CNS remains on Aβ monoclonal antibody treatments, with advancements expected to shift treatment towards earlier intervention populations [9]. - New delivery methods, such as systemic administration of small nucleic acids, are being explored as complementary approaches [9].